Mikrobiol. Z. 2020; 82(4):3-12. Ukrainian.
doi: https://doi.org/10.15407/microbiolj82.04.003

Anti-Lipopolysaccharide Antibodies and Osmotic Resistance of Erythrocytes in Healthy Individuals
and Patients with B-Cell Non-Hodgkin Lymphoma with Different Blood Groups

L.D. Varbanets1, K.G. Garkava2, O.S. Brovarskaya1, T.V. Bulyhina1,
V.V. Timoshenko3, R.P. Pavlyuk3, S.O. Sivkovych3

1Zabolotny Institute of Microbiology and Virology, NAS of Ukraine
154 Akad. Zabolotny Str., Kyiv, 03143, Ukraine

2National Aviation University
1 Lyubomyr Huzar Ave., Kyiv, 03680, Ukraine

3Institute of Hematology and Transfusion, NAMS of Ukraine
12 M. Berlinsky Str., Kyiv, 04060, Ukraine

Lipopolysaccharides (LPS) of gram-negative bacteria are obligate components of normal human antigenic environment, because they make up a large part of the gastrointestinal tract microbiota, represented by opportunistic enterobacteria. Therefore, a relatively stable baseline level of LPS-specific antibodies of different classes is always detected in human blood. Since LPS are polyclonal B-lymphocyte stimulators, they may contribute to the development of some tumor diseases associated with their activation, including B-cell non-Hodgkin lymphoma (B-NHL), which is a heterogeneous group of tumors originating from B-lymphocytes, which are at different stages of development and maturation. The purpose of this study was to evaluate the presence of antibodies to LPS isolated from three strains of Enterobacteriaceae, representatives of Escherichia coli and Pantoea agglomerans, in the blood of donors with different blood groups and patients with B-NHL. Results. The studies on determination the titer of antibodies to LPS of various representatives of Enterobacteriaceae indicate that blood donors, regardless of their group affiliation, have antibodies to LPS isolated from three bacterial strains – Escherichia coli L-19 (LPS 1), E. coli M-17 (LPS 2), and Pantoea agglomerans 8488 (LPS 3). The antibody titers differed depending on group affiliation. Thus, titer of antibodies to LPS 1 and LPS 2 was higher in the blood of blood group III donors than those of blood groups I, II or IV donors. Another data was obtained for B-NHL patients who did not have any specific treatment: the titer of anti-LPS antibodies in their blood was significantly lower than in healthy patients. However, the titers of antibodies to LPS 3 were slightly higher than to LPS 1 and LPS 2, especially in blood group III patients. Conclusions. Blood group B (III) donors are characterized by a highest titer of anti-LPS antibodies to E. coli L-19 (LPS 1), which may indicate a higher sensitivity to LPS, although the level of antibodies in the blood of all donors was higher compared to patients with B-NHL. This fact may need to be taken into account in blood transfusions in leukemia cases and the level of anti-LPS antibodies in the blood of donors should be detected.

Keywords: Escherichia coli, Pantoea agglomerans, lipopolysaccharides, anti-lipopolysaccharide antibodies, blood groups, B-cells non-Hodgkin lymphoma.

Full text (PDF, in Ukrainian)

  1. Riehl T, Cohn S, Tessner T, Schloemann S, Stenson WF. Lipopolysaccharide is radioprotective in the mouse intestine through a prostaglandin-mediated mechanism. Gastroenterology. 2000; 118(6):1106–1116. https://doi.org/10.1016/S0016-5085(00)70363-5
  2. De Soyza A, Silipo A, Lanzetta R, Govan JR, Molinaro A. Chemical and biological features of Burkholderia cepacia complex lipopolysaccharides. Innate Immun. 2008; 14:127–144. https://doi.org/10.1177/1753425908093984
  3. McAleer JP, Vella AT. Understanding how lipopolysaccharide impacts CD4 T cell immunity. Crit Rev Immunol. 2008; 28(4):281–299. https://doi.org/10.1615/CritRevImmunol.v28.i4.20
  4. Cross AS. Anti–endotoxin vaccines: back to the future. Virulence, 2014; 5:219–225. https://doi.org/10.4161/viru.25965
  5. Dieterich W, Schink M, Zopf Y. Microbiota in the Gastrointestinal Tract. Med Sci. 2018; 6(4):116. https://doi.org/10.3390/medsci6040116
  6. Shanko VM, Perfilieva MJ, Mochalova IS, Stupnitskaya NS, Zhurba TA. [Changes in the functional activity of human lymphocytes under the influence of Haemophilus influenzae lipopolysaccharides]. In.: Medicine: challenges of today: proceedings of IV Intern. scientific conf; 2017 Nov; Moscow, Russia. Moscow: Buki-Vedi, 2017. p. 6–10. Russian.
  7. Springer GF, Williamson P, Brandes WC. Blood group activity of gram-negative bacteria. J Exp Med. 1961; 113(6):1077–1093. https://doi.org/10.1084/jem.113.6.1077
  8. Ewald DR, Sumner SCJ. Human microbiota, blood group antigens, and disease. Wiley Interdiscip Rev Syst Biol Med. 2018; 10(3):e1413. https://doi.org/10.1002/wsbm.1413
  9. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 1998; 282:2085–2088. https://doi.org/10.1126/science.282.5396.2085
  10. Piazza F, Yu L, Teghanenemt A, Gioannini T, Weiss J, Peri F. Evidence of a specific interaction between new synthetic antisepsis agents and CD14. Biochemistry. 2009; 48(1):12337–12344. https://doi.org/10.1021/bi901601b
  11. Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K, Kimoto M. J Exper MD-2, a Molecule that Confers Lipopolysaccharide Responsiveness on Toll-like Receptor 4. Med. 1999; 189:1777–1782. https://doi.org/10.1084/jem.189.11.1777
  12. Nagai Y, Akashi S, Nagafuku M, Ogata M, Iwakura Y, Akira S, Kitamura T, Kosugi A, Kimoto M, Miyake K. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol. 2002; 3:667–672. https://doi.org/10.1038/ni809
  13. Resman N, Vasl J, Oblak A, Pristovsek P, Gioannini T. Essential roles of hydrophobic residues in both MD-2 and toll-like receptor 4 in activation by endotoxin. J Biol Chem. 2009; 284(22):15052–15060. https://doi.org/10.1074/jbc.M901429200
  14. Medzhitov R, Janeway C. Innate immunity. N Engl J Med. 2000; 343:338–344. https://doi.org/10.1056/NEJM200008033430506
  15. Shevchenko AI, Sidorenko AM, Krohmalnaya ER. [Epidemiology of Non-Hodgkin Lymphomas in the 20th and at the beginning of the 21st century]. Pathologia. 2014; 3(32):4–9. Ukrainian.
  16. Dotan E, Aggarwal C, Smith MR. Impact of rituximab (rituxan) on the treatment of B-cell non-Hodgkin’s lymphoma. Pharmacy and Therapeutics. 2010; 35(3):148–157.
  17. Forman D, Bray F, Brewster DH, GombeMbalawa C, Kohler B, Pineros M, Steliarova-Fouther E, Swaminathan R, Ferlay J. Cancer incidence in five continents. Lyon, France: International agency foe research on cancer; 2014.
  18. Lundin J, Checkoway H. Endotoxin and cancer. Environ Health Perspect. 2009;117(9):1344–1350. https://doi.org/10.1289/ehp.0800439
  19. Wang J, Cozen W, Thorne PS, et al. Household endotoxin levels and the risk of non-Hodgkin lymphoma. Cancer Causes Control. 2013; 24(2):357–364. https://doi.org/10.1007/s10552-012-0121-9
  20. Fudenberg HH, Pink JRL, Stites DP, Wang AC. Basic immunogenetics. New York; London; Toronto: Oxford University Press; 1972.
  21. Zdorovenko EL, Varbanets LD, Bin Liu, Wang Q, Valueva OA, Shashkov AS, Garkavaya EG, Brovarskaya OS, Wang Lei, Knirel YuA. Structure and gene cluster of the O-antigen of Escherichia coli L-19, a candidate for a new O-serogroup. Microbiology. 2014; 160:2102–2107. https://doi.org/10.1099/mic.0.080804-0
  22. Varbanets LD, Zdorovenko EA, Garkavaya EG, Brovarskaya OS. Lipopolysaccharide of Escherichia coli M-17. Microbiology. 2012; 81(3):324–331. https://doi.org/10.1134/S0026261712020154
  23. Bulyhina TV, Zdorovenko EL, Varbanets LD, Shashkov AS, Kadykova AA, Knirel YA, Lushchak OV. Structure of O-polysaccharide and lipid A of Pantoea agglomerans 8488. Biomolecules. 2020; 10(804). https://doi.org/10.3390/biom10050804
  24. Drannik GN, Dizik GM. [Genetic systems of human blood and disease]. Kyiv: Healthy, 1990. Russian.
  25. Vyazov OE. [Laboratory research methods in non-infectious immunology]. Moscow: Medicine, 1967. Russian.
  26. Bazarnova MA, Morozova VT. [Guide to practical exercises in clinical laboratory diagnostics]. Kyiv: Vyshka school, 1988. Russian.
  27. Prokopenko LG, Siplivaya LE. [Erythrocytes as modulators of immunological responses]. The successes of the physiological sciences. 1992; 23(4):89–106. Russian.
  28. Mineeva NV. [Human blood types]. Osnovyi immunologii. SPb: A-print, 2010. Russian.
  29. Wintrobe MM, Greer JP. Wintrobe’s clinical hematology. 12th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2009.
  30. Green C. The AB0, Lewis and related blood group antigens; a review of structure and biosynthesis. FEMS Microbiology Immunology. 1989; 47:321–330. https://doi.org/10.1111/j.1574-6968.1989.tb02417.x
  31. Poverennyy AM, Zamulayeva YA, Sayenko AS, Lekakh YV. [Hidden natural antibodies cause lymphocyte apoptosis]. Immunology. 2000; 4:39–42. Ukrainian.
  32. Krivitskaya VZ. [Autoreactive antibodies are normal in viral infections]. Infection and immunity. 2013; 3(4):301–310. Russian. https://doi.org/10.15789/2220-7619-2013-4-301-310
  33. Brändlein S, Pohle T, Ruoff N, Wozniak E, Müller-Hermelink H-K, Vollmers H. Natural IgM antibodies and immunosurveillance mechanisms epithelial cancer cells in humans. Cancer Res. 2003; 63:7995–8005.
  34. Prokopenko LG, Konoplya AI. [Metabolic immunomodulation]. Kursk: KSMU, 2000. Russian.